BRD4-TARGETED THERAPY ABBV-744 CLINICAL DATA NO FURTHER A MYSTERY

In Segment A, participants will acquire distinctive doses and schedules of oral ABBV-744 tablet to discover Protected dosing regimen. Additional contributors might be enrolled for the recognized monotherapy dosign program. In Section B, participants will get oral ruxolitinib and ABBV-744 will likely be offered as "add-on" therapy. In Section C, par